Asaf Levartovsky

Gastro doc || Pushing boundaries in GI and innovation at @sheba_medical || Focus on #AI, #IBD & #EoE

[NEJM @NEJM]

Neutralizing interleukin-10 autoantibodies were found in a subgroup of patients with inflammatory bowel disease and in no controls without IBD. Seropositivity was strongly associated with the IBD HLA-DRB1*01:03 risk allele. Full study results: https://t.co/C5oIChPFbG

Science behind the Study: Autoantibodies against Cytokines — From Infection to Inflammation https://t.co/Ja8nORGjYr

[Asaf Levartovsky @TheAlavra]

@Bealoquebea @jalpa_devi @MaiaKayalMD @ShomronH @rafeeq_rm @GorelikYuri @Y_ECCO_IBD @z_bakhshiii This is absolute brilliance. Waiting for this specific cheat sheet for a long time. Thanks! @Bealoquebea

[Beatriz Gros @Bealoquebea]

1/ A resident asked me how to interpret the two UC guselkumab trials

Same drug (IV/SC induction). Different trial designs, denominators & clinical meaning!

QUASAR = responder re-randomization
ASTRO = randomized treat-through

✅ key lesson: before comparing numbers, understand the design

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Joseph Sleiman, MD, FACP @JosephHabibi_MD]

#CGH4ALL @AGA_CGH
📣 Exciting data in #EoE: A potential step toward restoring dietary freedom while maintaining disease control in EoE.

🔹Open-label pilot study, patients (6–25 yrs) w/ milk/egg/soy/wheat-triggered EoE
🔹Dupilumab for 3 months, followed by stepwise food reintroduction up to 12 months
🔹All completers successfully reintroduced ≥1 trigger food, and many expanded diets every 3 months

#GITwitter #MedTwitter

🔗https://t.co/dManUlSOps

Reported by @AasthaBharwad

@EdoardoSavarino, @NdeBortoli, @SebastianZeki, @stevenbollipo, @DrCJudge, @my_ueg, @virgisolitano, @eathar_s, @DaniyalAbbasMD

[Alfredo J Lucendo @AlfredoLucendo]

🌍¡Comienza la cuenta atrás! El 22 de mayo es el Día Mundial de la EoE 2026. 🎗️La esofagitis eosinofílica afecta a miles de personas, pero que sigue siendo invisible para muchos. Es hora de unir nuestras voces para apoyar. No te pierdas el video oficial https://t.co/2gJoP5ugcc

[Asaf Levartovsky @TheAlavra]

@Pacufo @AlfredoLucendo Great job raising awareness
#EoE

[Asaf Levartovsky @TheAlavra]

Busted...

[Francis Deng, MD @francisdeng]

This #journalimage was AI-manipulated and retracted in NEJM.

Can you spot the signs?

[Shomron Ben-Horin @ShomronH]

Rewarding to see our @HabermanLab study featured on the cover, laying the conceptual framework to underlying mechanism of escape from AT remission (=flare) d/t persistent dietary-metabolic gut perturbances. Hence the need for combined AT-nutrition trials
@HelmsleyTrust

[NBA @NBA]

DENI DELIVERED.

[NEJM @NEJM]

A new article summarizes the epidemiology, diagnosis, and management of celiac disease and highlights serologic testing, biopsy confirmation, associated autoimmune conditions, and a gluten-free diet as treatment.

Read the Clinical Practice article “Celiac Disease” by Joseph A. Murray, MD, and Steffen Husby, MD, DMSc, from @mayoclinic and the University of Southern Denmark: https://t.co/mK3xminnKI

[Asaf Levartovsky @TheAlavra]

@GorelikYuri @NatureMedicine Makes me wonder about are afternoon (sesia) treatments...

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New research - Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

https://t.co/WhBmg8MWfW

#GITwitter

[Asaf Levartovsky @TheAlavra]

Do LLMs change their ethics based on who the patient is?

Our new paper in @JAMANetworkOpen suggests they can.

Such biases may shape #GI decision-making. It challenges the validity and equity of AI-supported clinical practice.

@UriKopylov @EyalKlang

https://t.co/auKF859yQF

[ron notkin @notkin1985]

זה אחד הדברים ההזויים. בגלל ש-70-40 אחוז מאמהות לילדים עם אוטיזם - מאמינות שחיסון גרם לאוטיזם - אז זה אומר שזה נכון. לא מחקר ולא כלום. אמונה. אנחנו גמורים בריבוע

[Asaf Levartovsky @TheAlavra]

Our latest work out in @IBDJournals.
Important findings and insights on clinical practice and a great team effort pushing the field forward.

[Adam Goldman @Adam_goldman_]

New publication!

Our study shows that CADe introduction did not improve surveillance colonoscopy performance in #IBD patients.

Highlights the need for IBD-specific CADe tools & attention to physician-AI dynamics.

https://t.co/PSi3KWDJ7h

@IBDJournals @UriKopylov @ShomronH

[Beatriz Gros @Bealoquebea]

Comparative Safety of JAKi vs AntiTNF in IMIDs SR&MA

➡️ 42 studies
🧑‍🤝‍🧑813,881 patients

Congratulations @virgisolitano @vipuljairath and rest of authors

https://t.co/91PBrrh3pk

[Asaf Levartovsky @TheAlavra]

@stevenbollipo So true. We feel it every day. It seems here they didn't have enough data for uni/multivariate analysis of endoscopist experience

[Asaf Levartovsky @TheAlavra]

@BraunEyal מדהים,באמת כל הכבוד למערך.
האם הבכירים במשרה חלקית במחלקה?

[Henit Yanai @HenitYanaiMD]

Proud to share the first #ECCO Consensus on Dietary Management of #IBD! 30+ experts & patient voices united to turn diet into therapy.
https://t.co/oPtc6s5ZON
Huge thanks to the incredible multidisciplinary team 🌍🙏 #Crohns #Colitis #DietMatters